Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 321Magnetic Resonance Spectroscopy 276pembrolizumab 265Carboplatin 190Cyclophosphamide 184Biopsy 179Cisplatin 163Paclitaxel 137Gemcitabine 137Bevacizumab 124fludarabine 119Nivolumab 117Radiotherapy 114Oxaliplatin 92Docetaxel 90venetoclax 89Fluorouracil 88Capecitabine 88Dexamethasone 86Pemetrexed 75Drug Therapy 73Rituximab 72Leucovorin 71durvalumab 70Blood Specimen Collection 69Radiosurgery 68atezolizumab 67Standard of Care 67Doxorubicin 65Radiation 63

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Paroxetine × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡